Delcath Systems Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Delcath Systems Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Queensbury
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- DCTH
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000872912
- EIN
- 06-1245881
Board of directors
-
Bridget A. Martell · DirectorSince 2024
-
Elizabeth Czerepak · DirectorSince 2023
-
Gerard J. Michel · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Gil Aharon · DirectorSince 2023
-
John Richard Sylvester · DirectorSince 2023
-
Roger G. Stoll Ph.D. · DirectorSince 2023
-
Steven A. J. Salamon · DirectorSince 2023
Chief executives
Gerard J. Michel
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of May 13, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
96.5%
-
97.0%
Board connections
4 of this board's directors also sit on 5 other boards.
- via Bridget A. Martell
- via Bridget A. Martell
- via Gerard J. Michel
- via Gil Aharon
- via Elizabeth Czerepak
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $287,457
- 4 purchases by 3 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 6, 2026 | Pennell Sandra Officer (Chief Financial Officer) | Open-market purchase | +5,533 | $9.04 | $50,018 |
| Mar 2, 2026 | Gerard J. Michel Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market purchase | +11,200 | $8.96 | $100,352 |
| Nov 21, 2025 | John Richard Sylvester Director | Open-market purchase | +4,386 | $8.89 | $38,992 |
| Nov 11, 2025 | Gerard J. Michel Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market purchase | +11,500 | $8.53 | $98,095 |
| Jun 12, 2025 | Vukovic Vojo Officer (CHIEF MEDICAL OFFICER) | Option exercise | +42,000 | $4.78 | $200,760 |
| May 5, 2025 | Gil Aharon Director | In-the-money exercise | +400,000 | $10.00 | $4,000,000 |
| May 5, 2025 | Steven A. J. Salamon Director | In-the-money exercise | +400,000 | $10.00 | $4,000,000 |
| May 5, 2025 | Steven A. J. Salamon Director | In-the-money exercise | +400,000 | $10.00 | $4,000,000 |
| Dec 24, 2024 | Steven A. J. Salamon Director | Derivative conversion | +250,000 | $10.00 | $2,500,000 |
| Dec 24, 2024 | Gil Aharon Director | Derivative conversion | +250,000 | $10.00 | $2,500,000 |
| Dec 24, 2024 | Rosalind Advisors, Inc. Director | Derivative conversion | +250,000 | $10.00 | $2,500,000 |
| Oct 22, 2024 | Gerard J. Michel Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise | +16,666 | $6.00 | $99,996 |
| Apr 18, 2024 | Gil Aharon Director | In-the-money exercise | +619,946 | $6,199.46 | $3,843,330,429 |
| Apr 18, 2024 | Steven A. J. Salamon Director | Derivative conversion | +991,615 | — | — |
| Apr 18, 2024 | Rosalind Advisors, Inc. Director | In-the-money exercise | +619,946 | $6,199.46 | $3,843,330,429 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.